OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
October 03, 2022
Various advances in contamination control are being utilized to reduce the chance pollutants contaminate a drug product.
October 02, 2022
Awareness of recently implemented—or ongoing—advances by the pharmacopoeias can help biotherapeutic manufacturers remain compliant with current requirements.
Whether biologic manufacturers decide to outsource or develop products internally, the quality of a CDMO partnership is critical to success, especially for cell and gene therapy products.
A blended approach to newly revised regulatory guidance to inform environmental monitoring programmes is essential.
Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.
Pharmaceutical Technology Europe pays tribute to the role Her Majesty Queen Elizabeth II had in promoting innovation within life sciences.
Under the revised NIS-2 Directive in Europe, pharma companies will need to be proactive in safeguarding their digital assets.
FDA backs joint reviews, common research policies, and modern production methods around the world.
One can only learn the secrets of "fight club" by attending its meetings.
Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, addresses the difference between regulatory compliance and real compliance.